Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07212998 · ClinicalTrials.gov registry record · Phase 3
Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) Trial
A Phase 3 study, sponsored by Jason Sperry.
- Not yet
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
NCT07212998 is a Phase 3 study that has not yet begun recruiting, run by Jason Sperry. The registered enrollment target is 750 participants.
The verdict
NCT07212998, a Phase 3 study, has not yet begun recruiting, sponsored by Jason Sperry.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
Study Summary
The Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) trial will be a 5-year (3-year enrollment), open label, phase-3, multi-center, early in-hospital phase randomized trial utilizing burn centers from within the LITES network and will enroll approximately 750 injured adult patients who have suffered large 2nd or 3rd degree thermal burns on at least 20% of their body surface requiring burn resuscitation. The objective is to determine if initiating plasma resuscitation as soon as possible upon arrival to an emergency department or burn unit is the most effective resuscitation for those who have experienced large thermal burns and significantly reduces the morbidity and mortality attributable to post-injury complications as compared to standard in-hospital resuscitation practice.
Interventions
- BIOLOGICAL Plasma
- BIOLOGICAL Standard care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2026-08 |
| Est. Completion | 2029-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07212998
The ClinicalTrials.gov registry entry for NCT07212998 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jason Sperry, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Plasma is the first listed.
NCT07212998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07212998 about?
NCT07212998 is a clinical study titled "Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) Trial". The Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) trial will be a 5-year (3-year enrollment), open label, phase-3, multi-center, early in-hospital phase randomized trial utilizing burn centers from within the LITES network and will enroll approxima...
What is the current status of trial NCT07212998?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2026-08. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07212998?
The interventions under investigation include: Plasma (BIOLOGICAL), Standard care (BIOLOGICAL).
Who is sponsoring clinical trial NCT07212998?
This trial is sponsored by Jason Sperry, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.